OncoMatch/Clinical Trials/NCT05035147
Albumin-bound Paclitaxel Combined With Gemcitabine First-line Inoperable Pancreatic Cancer
Is NCT05035147 recruiting? Yes, currently enrolling (Jun 2026). This Phase 4 trial studies albumin-bound paclitaxel for pancreatic cancer.
Treatment: albumin-bound paclitaxel — This study aims to further observe and evaluate whether the three-week administration of albumin-bound paclitaxel combined with gemcitabine is equivalent to the four-week administration in the treatment of inoperable locally advanced or metastatic pancreatic cancer
Check if I qualifyExtracted eligibility criteria
Treatments studied
Chemotherapy
Cancer type
Pancreatic Cancer
Prior therapy
Lab requirements
Blood counts
Hb ≥90 g/L (no blood transfusion within 14 days); ANC ≥1.5×10^9/L; PLT ≥100×10^9/L
Kidney function
Cr ≤1.5x ULN or creatinine clearance rate ≥60 ml/min
Liver function
TBIL <1.5x ULN; ALT and AST ≤3x ULN, <5x ULN if liver metastasis
The main organs are functioning normally, that is, they meet the following standards: Routine blood examination: Hb≥90g/L (no blood transfusion within 14 days); ANC ≥1.5×109/L; PLT ≥100×109/L; Biochemical examination: ALB≥29 g/L (without ALB in 14 days), TBIL <1.5 times the upper limit of normal (ULN); ALT and AST≤3ULN, accompanied by liver metastasis, then ALT and AST<5×ULN; Cr ≤1.5×ULN or creatinine clearance rate ≥60ml/min;
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT05035147 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages